Results from an open-label, single-arm prospective [PET] study indicate that reducing dosage of antipsychotics is feasible among patients with late-life schizophrenia and can improve extrapyramidal symptoms, hyperprolactinemia and other symptoms related to increases in dopamine D_2/3 receptor occupancies. {read more here}